Recently, the antibody drug-conjugate (ADC) approach has been adopted for delivering PROTACs into cancer cells that expressing cancer-specific membrane-anchored receptors, such as HER2 (Dragovich et al., 2020, 2021a,b; Maneiro et al., 2020; Pillow et al., 2020). Here, ERBB2 is linked to cancer.